Skip to main content

Table 2 Patient characteristics and outcome, cohort 2

From: Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Patient Response Characteristics (m1/f2; age (y3)) Phototype Histological type BRAF Status (wt7/mut8) Checkpoint inhibitor therapy Number of involved organs Metastasis Tumor Response at first CT scan11
1 Responders f, 35 n.a.4 SSM5 mut anti-PD19 + anti-CTLA410 4 Soft tissue, Lung, Liver, Spleen PR
2 m, 93 2 SSM wt anti-PD1 2 Lymph nodes, Lung SD*
3 f, 49 2 SSM mut anti-PD1 + anti-CTLA4 4 Lung, Liver, Lymph nodes, Brain PR
4 f, 43 3 SSM wt anti-PD1 4 Lung, Lymph nodes, Soft tissue, Brain PR
5 f, 54 2 SSM mut anti-PD1 2 Soft tissue, Lymph nodes PR
6 m, 48 n.a. nodular wt anti-PD1 3 Lymph nodes, Soft tissue, Bone PR
7 m, 57 2 nodular wt anti-PD1 7 Soft tissue, Lymph nodes, Kidney, Peritoneum, Lung, Bone, Brain SD*
8 f, 53 2 nodular mut anti-PD1 1 Lung SD*
9 m, 36 2 nodular wt anti-PD1 2 Lung, Lymph nodes PR
10 m, 75 n.a. nodular wt anti-PD1 1 Lung PR
11 m, 69 2 nodular wt anti-PD1 1 Soft tissue PR
12 f, 49 2 nodular wt anti-PD1 1 Lung PR
13 m, 30 4 nodular mut anti-PD1 1 Brain PR
14 m, 65 2 naevoid mut anti-PD1 + anti-CTLA4 4 Soft tissue, Lung, Lymph nodes, Brain PR
15 Non-Responders m, 79 2 LMM6 wt anti-PD1 2 Lymph nodes, Liver SD*
16 f, 52 2 SSM mut anti-CTLA4 5 Soft tissue, Lung, Liver, Mesenterium, Brain PD
17 m, 68 2 SSM wt anti-PD1 8 Soft tissue, Lymph nodes, Lung, Suprarenal gland, Liver, Intestinum, Bone, Brain PD
18 f, 58 3 nodular mut anti-PD1 1 Brain PD
19 m, 85 3 nodular wt anti-PD1 1 Brain PD
20 m, 60 3 nodular wt anti-PD1 + anti-CTLA4 3 Lymph nodes, Lung, Liver PD
21 m, 75 n.a. desmoplastic wt anti-PD1 2 Lymph nodes, Liver PD
  1. * pseudoprogression, 1male, 2female, 3years, 4not applicable, 5superficial spreading melanoma, 6lentigo maligna melanoma, 7wild type, 8V600E mutation, 9anti-programmed-cell-death-protein-1, 10anti-cytotoxic-T-lymphocyte-associated-protein-4, 11CR Complete Remission, PR Partial Remission, SD Stable Disease, PD Progressive Disease
Back to article page